{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:15:44Z","timestamp":1773839744867,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T00:00:00Z","timestamp":1758412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T00:00:00Z","timestamp":1758412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11739-025-04117-9","type":"journal-article","created":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:47:49Z","timestamp":1758426469000},"page":"2291-2294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GLP-1 and GIP agonists in diabetes and obesity and the rise of dyspepsia"],"prefix":"10.1007","volume":"20","author":[{"given":"Maria","family":"Masulli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Tack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-1134","authenticated-orcid":false,"given":"Giovanni","family":"Sarnelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,21]]},"reference":[{"key":"4117_CR1","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8:728\u2013742. https:\/\/doi.org\/10.1038\/nrendo.2012.140","journal-title":"Nat Rev Endocrinol"},{"key":"4117_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892","journal-title":"N Engl J Med"},{"key":"4117_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C (2020) A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med 382:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1916038","journal-title":"N Engl J Med"},{"issue":"6","key":"4117_CR4","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S2213-8587(25)00027-0","volume":"13","author":"N Sattar","year":"2025","unstructured":"Sattar N, Neeland IJ, Dahlqvist Leinhard O, Fern\u00e1ndez Land\u00f3 L, Bray R, Linge J, Rodriguez A (2025) Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol 13(6):482\u2013493. https:\/\/doi.org\/10.1016\/S2213-8587(25)00027-0. (Epub 2025 Apr 30 PMID: 40318682)","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"4117_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387(3):205\u2013216. https:\/\/doi.org\/10.1056\/NEJMoa2206038. (Epub 2022 Jun 4. PMID: 35658024)","journal-title":"N Engl J Med"},{"issue":"15","key":"4117_CR6","doi-asserted-by":"publisher","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","volume":"24","author":"QK Liu","year":"2024","unstructured":"Liu QK (2024) Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne) 24(15):1431292. https:\/\/doi.org\/10.3389\/fendo.2024.1431292. (PMID: 39114288; PMCID: PMC11304055)","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"4117_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP, SURMOUNT-5 Trial Investigators (2025) Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 393(1):26\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2416394. (Epub 2025 May 11. PMID: 40353578)","journal-title":"N Engl J Med"},{"key":"4117_CR8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/dom.12824","volume":"19","author":"K Bettge","year":"2017","unstructured":"Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA (2017) Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab 19:336\u2013347. https:\/\/doi.org\/10.1111\/dom.12824","journal-title":"Diabetes Obes Metab"},{"key":"4117_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","volume":"4","author":"MA Nauck","year":"2016","unstructured":"Nauck MA, Meier JJ (2016) The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol 4:525\u2013536","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4117_CR10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1172\/JCI990","volume":"101","author":"A Flint","year":"1998","unstructured":"Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515\u2013520. https:\/\/doi.org\/10.1172\/JCI990","journal-title":"J Clin Invest"},{"issue":"6","key":"4117_CR11","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.14309\/ajg.0000000000002519","volume":"119","author":"M Camilleri","year":"2024","unstructured":"Camilleri M, Lupianez-Merly C (2024) Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and implications in clinical practice. Am J Gastroenterol 119(6):1028\u20131037","journal-title":"Am J Gastroenterol"},{"issue":"24","key":"4117_CR12","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.3390\/diagnostics14242829","volume":"14","author":"SP Osei","year":"2024","unstructured":"Osei SP, Akomaning E, Florut TF, Sodhi M, Lacy BE, Aldhaleei WA, Bhagavathula AS (2024) Gastrointestinal safety assessment of GLP-1 receptor agonists in the US: a real-world adverse events analysis from the FAERS database. Diagn (Basel) 14(24):2829. https:\/\/doi.org\/10.3390\/diagnostics14242829","journal-title":"Diagn (Basel)"},{"issue":"6","key":"4117_CR13","doi-asserted-by":"publisher","first-page":"898","DOI":"10.7326\/ANNALS-24-03258","volume":"178","author":"MC Lovegrove","year":"2025","unstructured":"Lovegrove MC, Stone ND, Geller AI, Weidle NJ, Lind JN, Cohen PAUS (2025) Emergency department visits attributed by clinicians to semaglutide adverse events, 2022\u20132023. Ann Intern Med 178(6):898\u2013900. https:\/\/doi.org\/10.7326\/ANNALS-24-03258","journal-title":"Ann Intern Med"},{"issue":"1","key":"4117_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1053\/j.gastro.2024.04.001","volume":"168","author":"R Bansal","year":"2025","unstructured":"Bansal R, Khan R, Grover SC (2025) Measuring the quality and safety of upper endoscopy in patients taking glucagon-like peptide 1 receptor agonists. Gastroenterology 168(1):184\u2013185","journal-title":"Gastroenterology"},{"issue":"18","key":"4117_CR15","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.3390\/jcm13185627","volume":"13","author":"S Singh","year":"2024","unstructured":"Singh S, Chandan S, Dahiya DS, Aswath G, Ramai D, Maida M, Anderloni A, Muscatiello N, Facciorusso A (2024) Impact of GLP-1 receptor agonists in gastrointestinal endoscopy: an updated review. J Clin Med 13(18):5627","journal-title":"J Clin Med"},{"issue":"6","key":"4117_CR16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.14309\/ajg.0000000000002820","volume":"119","author":"B Hiramoto","year":"2024","unstructured":"Hiramoto B, McCarty TR, Lodhia NA, Jenkins A, Elnaiem A, Muftah M, Flanagan R, Chan WW (2024) Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management. Am J Gastroenterol 119(6):1126\u20131140","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"4117_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/ijo.2012.101","volume":"37","author":"A Rotondo","year":"2013","unstructured":"Rotondo A, Janssen P, Mul\u00e8 F, Tack J (2013) Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion. Int J Obes (Lond) 37(5):693\u2013698. https:\/\/doi.org\/10.1038\/ijo.2012.101","journal-title":"Int J Obes (Lond)"},{"issue":"10","key":"4117_CR18","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","volume":"9","author":"RJ Jalleh","year":"2024","unstructured":"Jalleh RJ, Rayner CK, Hausken T, Jones KL, Camilleri M, Horowitz M (2024) Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterol Hepatol 9(10):957\u2013964. https:\/\/doi.org\/10.1016\/S2468-1253(24)00188-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4117_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2025.06.012","author":"G Sarnelli","year":"2025","unstructured":"Sarnelli G, Pesce M, Barbara G, de Bortoli N, Sario AD, Esposito G, Frazzoni M, Galloro G, Gatta L, Ghisa M, Londoni C, Marabotto E, Meggio A, Pisani A, Ribolsi M, Usai Satta P, Savarino V, Scarpignato C, Stanghellini V, Tosetti C, Visaggi P, Zingone F, Barberio B, Savarino EV (2025) Italian guidelines for the diagnosis and treatment of functional dyspepsia\u2014joint consensus from the Italian societies of gastroenterology and endoscopy (SIGE), neurogastroenterology and motility (SINGEM), hospital gastroenterologists and endoscopists (AIGO), digestive endoscopy (SIED) and general medicine (SIMG). Dig Liver Dis. https:\/\/doi.org\/10.1016\/j.dld.2025.06.012. (Epub ahead of print. PMID: 40628573)","journal-title":"Dig Liver Dis"},{"issue":"1","key":"4117_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S2468-1253(24)00284-X","volume":"10","author":"J Schol","year":"2025","unstructured":"Schol J, Huang IH, Carbone F, Fernandez LMB, Gourcerol G, Ho V, Kohn G, Lacy BE, Colombo AL, Miwa H, Moshiree B, Nguyen L, O\u2019Grady G, Siah KTH, Stanghellini V, Tack J (2025) Rome Foundation and international neurogastroenterology and motility societies\u2019 consensus on idiopathic gastroparesis. Lancet Gastroenterol Hepatol 10(1):68\u201381. https:\/\/doi.org\/10.1016\/S2468-1253(24)00284-X","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-025-04117-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-025-04117-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-025-04117-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:02:58Z","timestamp":1764684178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-025-04117-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,21]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4117"],"URL":"https:\/\/doi.org\/10.1007\/s11739-025-04117-9","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,21]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors hereby affirm that there are no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement and Informed consent"}}]}}